Sandra Y. Vasey

1.9k total citations
22 papers, 890 citations indexed

About

Sandra Y. Vasey is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Sandra Y. Vasey has authored 22 papers receiving a total of 890 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Hematology, 9 papers in Molecular Biology and 5 papers in Genetics. Recurrent topics in Sandra Y. Vasey's work include Platelet Disorders and Treatments (12 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (7 papers) and Blood groups and transfusion (5 papers). Sandra Y. Vasey is often cited by papers focused on Platelet Disorders and Treatments (12 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (7 papers) and Blood groups and transfusion (5 papers). Sandra Y. Vasey collaborates with scholars based in United States, United Kingdom and Italy. Sandra Y. Vasey's co-authors include Bhabita Mayer, Mansoor N. Saleh, James B. Bussel, Nicole L. Stone, M. Arning, Gregory Cheng, Manuel Aivado, Claus Werenberg Marcher, Andrés Brainsky and Giampaolo Merlini and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Sandra Y. Vasey

21 papers receiving 867 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sandra Y. Vasey United States	11	637	193	183	132	107	22	890
Balkis Meddeb Tunisia	13	774 1.2×	241 1.2×	119 0.7×	189 1.4×	135 1.3×	50	1.0k
Ronan Desmond United States	13	1.1k 1.7×	259 1.3×	129 0.7×	41 0.3×	113 1.1×	30	1.4k
S Kuriya Japan	13	423 0.7×	144 0.7×	93 0.5×	58 0.4×	57 0.5×	51	567
Á Figuera Spain	17	545 0.9×	150 0.8×	48 0.3×	59 0.4×	52 0.5×	43	795
Naohito Fujishima Japan	19	598 0.9×	232 1.2×	167 0.9×	108 0.8×	55 0.5×	63	1.4k
Robert Delage Canada	18	400 0.6×	305 1.6×	141 0.8×	139 1.1×	17 0.2×	58	957
A. Wehmeier Germany	11	259 0.4×	235 1.2×	112 0.6×	29 0.2×	61 0.6×	31	591
Alessandro Lucchesi Italy	15	200 0.3×	193 1.0×	127 0.7×	47 0.4×	54 0.5×	54	460
Kelty R. Baker United States	10	207 0.3×	84 0.4×	128 0.7×	45 0.3×	29 0.3×	35	672
Z. Tellier France	15	550 0.9×	87 0.5×	198 1.1×	34 0.3×	45 0.4×	31	1.1k

Countries citing papers authored by Sandra Y. Vasey

Since Specialization

Citations

This map shows the geographic impact of Sandra Y. Vasey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sandra Y. Vasey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sandra Y. Vasey more than expected).

Fields of papers citing papers by Sandra Y. Vasey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sandra Y. Vasey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sandra Y. Vasey. The network helps show where Sandra Y. Vasey may publish in the future.

Co-authorship network of co-authors of Sandra Y. Vasey

This figure shows the co-authorship network connecting the top 25 collaborators of Sandra Y. Vasey. A scholar is included among the top collaborators of Sandra Y. Vasey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sandra Y. Vasey. Sandra Y. Vasey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rosenzweig, Michael, Yvonne A. Efebera, Efstathios Kastritis, et al.. (2023). Phase 2 Study of Daratumumab (DARA) Plus Bortezomib, Cyclophosphamide, and Dexamethasone (D-VCd) in a Diverse Patient Population with Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis: Aquarius. Blood. 142(Supplement 1). 4785–4785.

Minnema, Monique C., Angela Dispenzieri, Giampaolo Merlini, et al.. (2022). Outcomes by Cardiac Stage in Patients With Newly Diagnosed AL Amyloidosis. JACC CardioOncology. 4(4). 474–487. 12 indexed citations

Wechalekar, Ashutosh, Giovanni Palladini, Giampaolo Merlini, et al.. (2020). Rapid and Deep Hematologic Responses Are Associated with Improved Major Organ Deterioration Progression-Free Survival in Newly Diagnosed AL Amyloidosis: Results from Andromeda. Blood. 136(Supplement 1). 6–7. 5 indexed citations

Palladini, Giovanni, Efstathios Kastritis, Mathew S. Maurer, et al.. (2020). Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. Blood. 136(1). 71–80. 138 indexed citations

Minnema, Monique C., Angela Dispenzieri, Giampaolo Merlini, et al.. (2020). Outcomes By Cardiac Stage in Newly Diagnosed AL Amyloidosis: Results from Andromeda. Blood. 136(Supplement 1). 44–45. 4 indexed citations

Comenzo, Ray, Efstathios Kastritis, Mathew S. Maurer, et al.. (2019). S875 SUBCUTANEOUS DARATUMUMAB + CYCLOPHOSPHAMIDE, BORTEZOMIB, AND DEXAMETHASONE (CYBORD) IN PATIENTS WITH NEWLY DIAGNOSED AMYLOID LIGHT CHAIN (AL) AMYLOIDOSIS: UPDATED SAFETY RUN‐IN RESULTS OF ANDROMEDA. HemaSphere. 3(S1). 392–392. 10 indexed citations

Comenzo, Ray, Efstathios Kastritis, Mathew S. Maurer, et al.. (2018). Subcutaneous daratumumab (DARA SC) plus cyclophosphamide, bortezomib, and dexamethasone (CyBorD) in patients (Pts) with newly diagnosed amyloid light chain (AL) amyloidosis: Safety run-in results of andromeda.. Journal of Clinical Oncology. 36(15_suppl). 8011–8011. 8 indexed citations

Giannini, Edoardo G., Nezam H. Afdhal, Samuel H. Sigal, et al.. (2015). Non‐cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy. Journal of Gastroenterology and Hepatology. 30(8). 1301–1308. 4 indexed citations

Afdhal, Nezam H., Geoffrey Dusheiko, Edoardo G. Giannini, et al.. (2013). Eltrombopag Increases Platelet Numbers in Thrombocytopenic Patients With HCV Infection and Cirrhosis, Allowing for Effective Antiviral Therapy. Gastroenterology. 146(2). 442–452.e1. 98 indexed citations

10.

Tarantino, Michael D., Patrick Fogarty, Bhabita Mayer, Sandra Y. Vasey, & Andrés Brainsky. (2013). Efficacy of eltrombopag in management of bleeding symptoms associated with chronic immune thrombocytopenia. Blood Coagulation & Fibrinolysis. 24(3). 284–296. 8 indexed citations

11.

Bussel, James B., Mansoor N. Saleh, Sandra Y. Vasey, et al.. (2012). Repeated short‐term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP). British Journal of Haematology. 160(4). 538–546. 47 indexed citations

12.

Dusheiko, Geoffrey, Nezam H. Afdhal, Edoardo G. Giannini, et al.. (2011). Final Results of Open-Label Treatment with Eltrombopag During ENABLE 1: A Study of Eltrombopag As An Adjunct for Antiviral Treatment of Hepatitis C Virus Associated with Thrombocytopenia. Blood. 118(21). 2232–2232. 4 indexed citations

13.

Bussel, James B., Gregory Cheng, Mansoor N. Saleh, et al.. (2010). Incidence of Thromboembolic Events Across Eltrombopag Clinical Trials In Chronic Immune Thrombocytopenia (ITP). Blood. 116(21). 70–70. 14 indexed citations

14.

Cheng, Gregory, Mansoor N. Saleh, Claus Werenberg Marcher, et al.. (2010). Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. The Lancet. 377(9763). 393–402. 397 indexed citations

15.

Pabinger, Ingrid, Claus Werenberg Marcher, Abderrahim Khélif, Sandra Y. Vasey, & Andrés Brainsky. (2010). Effect of Eltrobopag on platelet response, bleeding and reduction in concomitant ITP medication in adults with chronic Immuno Thrombocytopenia (ITP) and baseline platelets = 15,000 /ml. University of Southern Denmark Research Portal (University of Southern Denmark). 1 indexed citations

16.

Cheng, Gang, JB Bussel, Claus Werenberg Marcher, et al.. (2009). A phase III, double-blind, placebo-controlled study (RAISE) of eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura (ITP). Journal of Thrombosis and Haemostasis. 2 indexed citations

17.

Bussel, James B., Gregory Cheng, Mansoor N. Saleh, et al.. (2009). Thromboembolic Events Observed in Eltrombopag Clinical Trials in Chronic Immune Thrombocytopenic Purpura.. Blood. 114(22). 2423–2423. 12 indexed citations

18.

Psaila, Bethan, J B Bussel, Sandra Y. Vasey, et al.. (2008). EFFICACY AND SAFETY OF REPEATED INTERMITTENT TREATMENT WITH ELTROMBOPAG IN PATIENTS WITH CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP). 93. 120–120. 2 indexed citations

19.

Bussel, James B., Bethan Psaila, Mansoor N. Saleh, et al.. (2008). Efficacy and Safety of Repeated Intermittent Treatment with Eltrombopag in Patients with Chronic Idiopathic Thrombocytopenic Purpura.. Blood. 112(11). 3431–3431. 18 indexed citations

20.

Cheng, Gregory, Mansoor N. Saleh, James B. Bussel, et al.. (2008). Oral Eltrombopag for the Long-Term Treatment of Patients with Chronic Idiopathic Thrombocytopenic Purpura: Results of a Phase III, Double- Blind, Placebo-Controlled Study (RAISE). Blood. 112(11). 400–400. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact